CTLA4 and adenocarcinoma: At present, the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, ipilimumab, did not reach the expected endpoint of improved progression free survival (PFS) and OS in advanced GC/GEJC adenocarcinoma (NCT01585987) (36).